Press releases

All Press releases are available in Swedish.

Cyxone's development substance T20K's capacity to prevent and inhibit multiple sclerosis in animal models now verified by independent study

Cyxone can announce today that an independent research group at Monash University in Australia has confirmed the positive effects of the company's development substance T20K on multiple sclerosis (MS) symptoms in animal models as previously described.

Cyxone's development programme includes the confirmation of the positive results achieved with T20K on MS in animal models that a research group at the Medical University of Vienna outlined in an article published in March 2016 in the respected PNAS scientific journal and elsewhere. It is standard procedure ahead of clinical trials to allow independent laboratories to confirm the effectiveness of a new drug that is intended to be developed into a competitive product.

The research group investigated whether T20K, through pre-treatment of animals with a single dose administered seven days before initiation of the disease, could prevent the animals from developing MS symptoms, and that daily treatment with T20K after initiation, could prevent the development of MS.

The study showed that only one dose of either 5 or 10 mg/kg of T20K seven days prior to the initiation of the disease significantly delayed the development of symptoms, reduced the extent of MS symptoms, and significantly reduced the overall development of the illness in the animals.

When the test animals were started on an oral treatment of T20K at the same time as the disease was initiated, T20K delayed and reduced the development of symptoms even at 1mg/kg/day. With a dose of 3mg/kg/day, the animals displayed no measurable MS symptoms. The positive control substance Fingolimod (Gilenya) applied at the same 3mg/kg/day dose, showed similar effects on MS symptoms as T20K.

The results from Monash University thereby confirm that T20K has both the capacity to prevent MS, and to treat existing MS. The new study also shows that T20K works at considerably lower doses than previously described. Complete inhibition of MS symptoms takes place with an oral dose of 3mg/kg/day, compared to the previous effective oral dose of 20mg/kg/day.

The results suggest that T20K has a very competitive effect on MS compared to today's leading MS product, Gilenya; and that the safety interval appears to be even greater than previously achieved.

Cyxone's CEO, Kjell Stenberg, says: "Although we never doubted the findings of the research group at the Medical University of Vienna, we're delighted that it's been demonstrated that T20K performs even better against MS in animal models than we had previously thought, which provides encouragement for our work in studying T20K's effects on humans." Cyxone's chairman, Bert Junno, says: "The new results from the Australian laboratory strengthens Cyxone's leading position in the development of safer more effective MS treatments."

March 10, 2017

Contact
Cyxone AB (publ.)
Kjell G. Stenberg, CEO
Tel: +46 (0) 723 816 168
Email: kjell.g.stenberg@cyxone.com
Adelgatan 21
211 22 Malmö
www.cyxone.com

This is information that Cyxone AB is required to publish under the EU Market Abuse Directive. The information was provided under the auspices of the above contact person for publication on March 10, 2017 at 13:00 CET.

About Cyxone
Cyxone AB (publ.) is a biopharmaceutical company that develops drugs based on cyclotides, a class of natural plant protein. Cyclotide technology has the potential to provide new drugs with beneficial pharmacological effects on diseases that currently lack safe and effective treatments. The company is focusing on the development of T20K, a substance that inhibits key processes in cells that are typically associated with various immune disorders, such as multiple sclerosis and rheumatoid arthritis. Cyxone's Certified Adviser on the Nasdaq First North is Erik Penser Bank.

February 16, 2018
Regulatory

Summary of the Year-end Report

Fourth Quarter (1 October to 31 December 2017)

  • Operating revenue KSEK 0 (21)
  • Income after financial items KSEK -3 231 (-1 301)
  • Earnings per share -0,18 (-0,10)
  • Cash and cash equivalents as of 31 December KSEK 33 357 (21 598)
  • Equity ratio as of 31 December 90,4 (96,9) %

Financial year (1 January to 31 December 2017)

  • Operating revenue KSEK 0 (21)
  • Income after financial items KSEK -8 824 (-4 162)
  • Earnings per share SEK -0,50 (-0,32)
Read more
January 31, 2018

In response to interest from drug companies, Cyxone is to review whether cyclotides are effective against inflammatory bowel disease (IBD). The study was planned by the Medical University of Vienna and is now underway.

Read more
December 11, 2017
Regulatory

Today, December 11, 2017, Cyxone AB (publ.) held an extraordinary general meeting. Below is an overview of the motions decided upon. All motions were taken with the necessary majority of votes.

Read more
November 23, 2017
Regulatory

Shareholders in Cyxone AB (publ.), 559020-5471, are hereby invited to an extraordinary general meeting at Setterwalls Advokatbyrå AB, Stortorget 23, in Malmö, on Monday, December 11, 2017 at 10:00AM.

Read more
November 23, 2017
Regulatory

As previously announced, Cyxone acquired Rabeximod from OxyPharma in June 2017. Rabeximod has undergone Phase 2 trials in patients with moderate to severe rheumatoid arthritis in which significant improvements in the condition's symptoms were discovered four weeks after the completion of the formal (12 week) trial period.

Read more
November 06, 2017
Regulatory

Cyxone has analysed the Rabeximod that was previously manufactured by OxyPharma for clinical trials at Syntagon AB. Results show that the existing substance, despite having been stored for several years, can be used in Cyxone's upcoming Phase 2b study in patients with rheumatoid arthritis.

Read more
October 26, 2017
Regulatory

Summary

Period (July 1 to September 30, 2017)

  • Operating revenue KSEK 0 (0)
  • Income after financial items KSEK -1,518 (-1,235)
  • Earnings per share SEK -0,10 (-0,10) Cash and cash equivalents as of September 30 KSEK 25,662 (23,468)
  • Equity ratio as of September 30 95.2% (97.7%)

Period (January 1 to September 30)

  • Operating revenue KSEK 0 (0)
  • Income after financial items KSEK -5,593 (-2,860)
  • Earnings per share SEK -0,36 (-0,22)
Read more
October 26, 2017
Regulatory
In co-operation with Taiwan-based Eurofins Panlabs Discovery Services, Cyxone has investigated whether T20K has the capacity to influence receptors or other cellular functions to shed light on the substance's potential side effects.
Read more
October 13, 2017
Regulatory

In collaboration with the Medical University of Vienna, Cyxone is set to conduct a study into inflammatory bowel disease involving a cyclotide in established animal models. The study will begin early in 2018.

Read more
1
2
3